Clinical Trials Logo

Acromegaly clinical trials

View clinical trials related to Acromegaly.

Filter by:

NCT ID: NCT00446082 Completed - Acromegaly Clinical Trials

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Start date: June 2006
Phase: Phase 1
Study type: Interventional

This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease

NCT ID: NCT00444873 Completed - Acromegaly Clinical Trials

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Start date: January 2005
Phase: Phase 3
Study type: Interventional

A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg.

NCT ID: NCT00383708 Completed - Acromegaly Clinical Trials

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Start date: October 2006
Phase: Phase 3
Study type: Interventional

The main aim of this study is to assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep sub-cutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via sub-cutaneous injection given once or twice a week) on IGF-1 levels over 28 weeks in acromegalic patients. The primary endpoint will be the percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.

NCT ID: NCT00376064 Completed - Acromegaly Clinical Trials

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Start date: March 2006
Phase: Phase 4
Study type: Interventional

This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy

NCT ID: NCT00372697 Completed - Acromegaly Clinical Trials

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.

NCT ID: NCT00234572 Completed - Acromegaly Clinical Trials

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Start date: May 2000
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of treatment given at titrated doses.

NCT ID: NCT00234520 Completed - Acromegaly Clinical Trials

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

Start date: May 2003
Phase:
Study type: Observational

The aim of the study is to compare the risk of acromegaly patients developing valvular regurgitation when receiving lanreotide or octreotide

NCT ID: NCT00225979 Completed - Acromegaly Clinical Trials

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

Start date: November 2002
Phase: Phase 3
Study type: Interventional

Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly. The objective of this study is to assess the safety and efficacy of long-acting repeatable formulation of octreotide and to compare it to the safety and efficacy of surgery in patients with acromegaly who have not had any previous treatment for acromegaly.

NCT ID: NCT00216398 Completed - Acromegaly Clinical Trials

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Start date: June 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.

NCT ID: NCT00210457 Completed - Acromegaly Clinical Trials

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Start date: September 2000
Phase: Phase 3
Study type: Interventional

To evaluate the long-term efficacy and safety of repeated injections of lanreotide Autogel given in doses titrated to effect in acromegalic patients previously treated or not with somatostatin analogues.